WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Amyris, Inc. | January 25, 2022
Amyris, Inc. a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ operating platform announces that it has agreed to exclusive terms to acquire the assets of MenoLabs, LLC, a women-founded company to treat menopause symptoms, drive research for women's health and improve society's understanding of menopause.
Amyris previously communicated its intention of launching a new consumer...
Avenge Bio, Inc. | August 23, 2022
Avenge Bio, Inc. a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced a publication in the peer-reviewed journal Clinical Cancer Research describing the foundational, preclinical data establishing the efficacy and safety of pleural administered LOCOcyte™ for the treatment of pleural malignant mesothelioma. The manuscript, entitled "Activation of adaptive...
Viva Biotech, BioMap | May 11, 2021
The first generation of the China Biocomputing Conference, hosted by BioMap and Adock, was successfully launched in Suzhou. The conference's goal is to bring together biotech and IT industry partners to build a multi-party integrated industrial ecosystem and realize AI's full potential in the field of biotechnology.
Viva Biotech was invited to the conference and announced a strategic alliance with BioMap. This alliance will combine BioMap's AI + biological computing en...
Envisagenics | December 05, 2022
Envisagenics, an Artificial Intelligence driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb. The multi-year collaboration will leverage Envisagenics' SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based ...
Cell and Gene Therapy
Cell and Gene Therapy, Industrial Impact
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE